Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer

Next Previous
Trial Profile

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary) ; Capecitabine; Carboplatin; Cyclophosphamide; Eribulin; Gemcitabine; Interferon; Retifanlimab; Taxanes; Vinorelbine
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASTRO-VAC CNS; BRIA-ABC
  • Sponsors BriaCell Therapeutics Corp

Most Recent Events

  • 16 Jul 2026 According to BriaCell Therapeutics media release, the company announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCells ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer.
  • 15 Jul 2026 According to a BriaCell Therapeutics media release, company has entered into a manufacturing agreement with FUJIFILM Biotechnologies California (CDMO) specializing in cell therapies, to support the ongoing pivotal Phase 3 clinical development of Bria-IMT.
  • 25 Jun 2026 According to BriaCell Therapeutics media release, the company has entered into a Memorandum of Understanding (MoU), with Uneedle to support the continued use and commercial readiness of Uneedle's proprietary microneedle technology for intradermal administration of Bria-IMT. This microneedle is being used in this pivotal study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top